Enhancing vaccine efficacy: Unlocking the power of adjuvants in global development

Vaccine adjuvants play a critical role in enhancing immune responses, enabling dose-sparing and fewer immunizations, and providing more durable protection. However, in low- and middle-income countries (LMICs), vaccine developers must contend with challenges such as cost restraints, limited cold-chain infrastructure, manufacturing scalability, and programmatic complexity.

Intended for LMIC vaccine manufacturers, this PATH-organized two-part webinar provides an overview of vaccine adjuvants, highlighting how adjuvants can enhance immune responses and support manufacturers in addressing these region-specific vaccination challenges. Topics include adjuvant types, immunological principles and mechanisms of action, regulatory considerations, manufacturing challenges, and strategies to improve vaccine efficacy and access.

The session features dialogue among researchers, vaccine manufacturers, adjuvant developers, and regulatory teams focused on the advancement, development, approval, and deployment of suitable adjuvants tailored for LMIC needs.

Speakers include:

  • Lakshmi Khandke, PhD, Senior Program Advisor, Vaccines CMC, Center for Vaccine Innovation and Access, PATH
  • Derek O’Hagan, PhD, Head of Vaccine Adjuvants and Delivery Systems, GSK
  • Mark Alderson, PhD, CSO and US Site Director, Maxvax Biotechnology
  • Julie Jospeh, PhD, Senior Biologist/Evaluator, Health Canada Centre for Vaccines, Clinical Trials, and Biostatistics
  • Daniel Fullen, PhD, Lead, R&D Innovations, Center for Epidemic Preparedness Innovations (CEPI)
  • Dennis Christensen, PhD, Head of Global Research and Development, Adjuvant Systems, Croda Pharma
  • Wolfgang Leitner, DSc, Chief of the Innate immunity Section of the Basic immunology Branch/Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID)
  • Jay Evans, PhD, Co-Founder and Chief Scientific & Strategy Officer, Inimmune Corporation and Director of the Center for Translational Medicine, University of Montana

Corporate author(s): PATH, GSK, Maxvax Biotechnology, Health Canada, CEPI, Croda Pharma, NIAID, Inimmune Corporation, University of Montana

Publication date: June 2026

Available materials

  1. English

    1. Day 1 speaker slides: Julie Joseph 1.7 MB PDF
    2. Day 1 speaker slides: Mark Alderson 2 MB PDF
    3. Day 2 speaker slides: Daniel Fullen 3.2 MB PDF
    4. Day 2 speaker slides: Dennis Christensen 3 MB PDF
    5. Day 2 speaker slides: Wolfgang Leitner 2.6 MB PDF
    6. Day 2 speaker slides: Jay Evans 5.5 MB PDF

  2. English

    1. Webinar: Part 1
    2. Webinar: Part 2